Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?

Literature DB >> 27430580

Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?

Abstract

Findings within the current issue indicate that treatment with IPH2101 when used as a monotherapy in smoldering multiple myeloma, meant to enhance natural killer (NK) cell function through inhibitory KIR blockade, results in a surprising reduction of NK-cell function mediated through monocyte trogocytosis. The significance of these findings is discussed. Clin Cancer Res; 22(21); 5161-3. ©2016 AACRSee related article by Carlsten et al., p. 5211. ©2016 American Association for Cancer Research.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 27430580 PMCID： PMC5093060 DOI： 10.1158/1078-0432.CCR-16-1582

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

12 in total

1. Education of hyporesponsive NK cells by cytokines.

Authors: Kerstin Juelke; Monica Killig; Andreas Thiel; Jun Dong; Chiara Romagnani
Journal: Eur J Immunol Date: 2009-09 Impact factor: 5.532

2. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Authors: Nidale Tarek; Jean-Benoit Le Luduec; Meighan M Gallagher; Junting Zheng; Jeffrey M Venstrom; Elizabeth Chamberlain; Shakeel Modak; Glenn Heller; Bo Dupont; Nai-Kong V Cheung; Katharine C Hsu
Journal: J Clin Invest Date: 2012-08-06 Impact factor: 14.808

3. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors: Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal: Clin Cancer Res Date: 2015-05-21 Impact factor: 12.531

4. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Authors: Neha Korde; Mattias Carlsten; Min-Jung Lee; Alex Minter; Esther Tan; Mary Kwok; Elisabet Manasanch; Manisha Bhutani; Nishant Tageja; Mark Roschewski; Adriana Zingone; Rene Costello; Marcia Mulquin; Diamond Zuchlinski; Irina Maric; Katherine R Calvo; Raul Braylan; Prashant Tembhare; Constance Yuan; Maryalice Stetler-Stevenson; Jane Trepel; Richard Childs; Ola Landgren
Journal: Haematologica Date: 2014-03-21 Impact factor: 9.941

5. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Authors: Don M Benson; Courtney E Bakan; Shuhong Zhang; Shauna M Collins; Jing Liang; Shivani Srivastava; Craig C Hofmeister; Yvonne Efebera; Pascale Andre; Francois Romagne; Mathieu Bléry; Cécile Bonnafous; Jianying Zhang; David Clever; Michael A Caligiuri; Sherif S Farag
Journal: Blood Date: 2011-10-26 Impact factor: 22.113

6. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Authors: Don M Benson; Craig C Hofmeister; Swaminathan Padmanabhan; Attaya Suvannasankha; Sundar Jagannath; Rafat Abonour; Courtney Bakan; Pascale Andre; Yvonne Efebera; Jérôme Tiollier; Michael A Caligiuri; Sherif S Farag
Journal: Blood Date: 2012-10-01 Impact factor: 22.113

7. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

Authors: Norbert Vey; Jean-Henri Bourhis; Nicolas Boissel; Dominique Bordessoule; Thomas Prebet; Aude Charbonnier; Anne Etienne; Pascale Andre; François Romagne; Don Benson; Herve Dombret; Daniel Olive
Journal: Blood Date: 2012-09-21 Impact factor: 22.113

8. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.

Authors: Joshua Richter; Natalia Neparidze; Lin Zhang; Shiny Nair; Tamara Monesmith; Ranjini Sundaram; Fred Miesowicz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal: Blood Date: 2012-10-24 Impact factor: 22.113

9. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.

Authors: Gustaf Vahlne; Katja Lindholm; Anders Meier; Stina Wickström; Tadepally Lakshmikanth; Frank Brennan; Michael Wilken; Rikke Nielsen; François Romagné; Nicolai R Wagtmann; Klas Kärre; Maria H Johansson
Journal: Eur J Immunol Date: 2010-03 Impact factor: 5.532

Review 10. Unifying concepts of MHC-dependent natural killer cell education.

Authors: Julie M Elliott; Wayne M Yokoyama
Journal: Trends Immunol Date: 2011-07-13 Impact factor: 16.687

6 in total

Review 1. Challenges of NK cell-based immunotherapy in the new era.

Authors: Fang Fang; Weihua Xiao; Zhigang Tian
Journal: Front Med Date: 2018-07-25 Impact factor: 4.592

Review 2. Trial watch: Immune checkpoint blockers for cancer therapy.

Authors: Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2017-08-31 Impact factor: 8.110

Review 3. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors: Min Yu; Zonghai Li
Journal: Front Med Date: 2017-08-05 Impact factor: 4.592